VilazodoneIn Major Depressive Disorder

被引：0
作者：
James E. Frampton
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
CNS Drugs | 2011年 / 25卷
关键词：
Major Depressive Disorder; Selective Serotonin Reuptake Inhibitor; Forced Swimming Test; MADRS Total Score; Vilazodone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Vilazodone, a novel antidepressant agent that combines selective serotonin reuptake inhibitor (SSRI) activity and serotonin 5-HT1A receptor partial agonist activity in a single molecule, is indicated for the treatment of major depressive disorder (MDD) in the US. It is administered orally, once daily, with food.
引用
收藏
页码：615 / 627
页数：12
相关论文
共 66 条
  • [1] Greden JF(2001)The burden of recurrent depression: causes, consequences, and future prospects J Clin Psychiatry 22 5-9
  • [2] Kessler RC(1995)Posttraumatic stress disorder in the national comorbidity survey Arch Gen Psychiatry 52 1048-60
  • [3] Sonnega A(2008)Depression in the medically ill: diagnostic and therapeutic implications Curr Psychiatry Rep 10 272-9
  • [4] Bromet E(2008)Blues from the neighbourhood? Neighbourhood characteristics and depression Epidemiol Rev 30 101-17
  • [5] Narasimhan M(2010)The future of psychopharmacology of depression J Clin Psychiatry 71 971-5
  • [6] Raynor JD(2009)First-line pharmacotherapies for depression: what is the best choice? Pol Arch Med Wewn 119 478-85
  • [7] Jones AB(2009)Problems associated with long-term treatment with selective serotonin reuptake inhibitors J Psychopharmacol 23 967-74
  • [8] Kim D(2009)Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 6 53-77
  • [9] Chang T(2010)Antidepressants: current strategies and future opportunities Curr Pharm Des 16 4243-53
  • [10] Fava M(2010)Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systemic review J Psychopharmacol 24 513-20
1234567